Pneumococcal Vaccine Market Size 2024-2028

The global pneumococcal vaccine market size is estimated to grow by USD 2.85 billion, at a CAGR of 5.6% between 2023 and 2028. The market is expanding due to several factors, including the notable growth driven by expanding immunization programs by governments in developing countries. Additionally, advancements in vaccine technologies represent a key trend, enhancing the effectiveness and accessibility of these vaccine. However, the market faces a significant challenge in the high cost of vaccine research and development and production, which can hinder availability, particularly in low-income regions. As global efforts to combat pneumonia increase, the demand for pneumococcal vaccines continues to rise, emphasizing the need for affordable manufacturing and distribution solutions. By overcoming these challenges and leveraging innovative technologies, stakeholders can improve vaccine access and ultimately contribute to better health outcomes for vulnerable populations.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:

Astellas Pharma Inc - The company offers pneumococcal vaccine solutions such as Multiple Antigen Presenting System to advance a novel MAPS vaccine targeted to prevent and reduce the spread of Streptococcus pneumoniae disease.

Biological E. Ltd., CSL Ltd., GlaxoSmithKline Plc, Inventprise Inc., Merck and Co. Inc., Panacea Biotec Ltd., Petrovax, Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Sinovac Biotech Ltd., SK Inc., Vaxcyte Inc., and Walvax Biotechnology Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Type Outlook
  • Pneumococcal conjugate vaccine
  • Pneumococcal polysaccharide vaccine

• Distribution Channel Outlook
  • Non-governmental organizations
  • Government authorities
  • Distribution partner companies

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • South America
    • Chile
    • Brazil
    • Argentina
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa

By Type Insights

The market share growth by the pneumococcal conjugate vaccine segment will be significant during the forecast period.  The pneumococcal vaccine holds a pivotal role in mitigating the impact of pneumococcal pneumonia, an invasive disease caused by Streptococcus pneumoniae. This contagious disease can lead to severe complications, including sepsis, meningitis, and pneumonia, which can be fatal, particularly in vulnerable populations such as the immunocompromised, geriatric population, and those with underlying conditions like chronic heart disease, diabetes, human immunodeficiency, and splenectomy. Despite advancements in medical research, pneumococcal pneumonia remains a pandemic threat, causing significant morbidity and mortality. However, the advent of this vaccine has led to a marked reduction in pneumonia cases and related complications.

Get a glance at the market contribution of various segments Download PDF Sample

The pneumococcal conjugate vaccine was the largest and was valued at USD 6.71 billion in 2018. The vaccine's success is attributed to its ability to protect against various strains of Streptococcus pneumoniae, making it an essential component of pediatric and adult immunization programs. The vaccine is administered through various routes, including intramuscular injections and intranasal sprays, and is available at pharmacies and community clinics. Pipeline studies and research activities are ongoing to develop novel pneumococcal vaccines, including protein-based vaccines, and explore the potential of booster doses to enhance the vaccine's efficacy. Despite the vaccine's prominence, adverse reactions such as redness, headache, tiredness, and generalized muscle pain are common, particularly after the first dose. Bacterial meningitis, a rare but serious complication, is a potential concern, but the benefits of the vaccine far outweigh the risks.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period.  The market in this region has experienced significant expansion due to the increasing incidence of pneumococcal diseases and the implementation of immunization programs. Hospitalizations and mortality rates associated with these diseases underscore the importance of vaccination. Demographic groups at higher risk, such as young children and the elderly, further focus the need for effective vaccine manufacturing and distribution. Economic disparities can impact vaccine accessibility, making it crucial for initiatives to address these disparities and ensure equitable distribution of vaccines against various pneumococcal strains.

Market Dynamics and Customer Landscape

The market holds significance due to the prominence of pneumococcal diseases, including invasive pneumococcal pneumonia and bacterial meningitis. According to research activities, pipeline studies are underway to develop novel pneumococcal vaccines to address the increasing number of pneumonia cases caused by various pneumococcal strains. These vaccines are crucial for preventing complications such as lung disease, sinusitis, and even life-threatening conditions like sepsis, which can lead to hospitalizations and high mortality rates. Demographic groups at higher risk, such as those with chronic heart disease, diabetes, human immunodeficiency, and generalized musculoskeletal disorders, are prioritized for immunization programs. Economic disparities and vaccine accessibility remain challenges in ensuring widespread protection against pneumococcal diseases. Protein-based vaccines are the current mainstay, and ongoing research aims to improve their efficacy and safety. Vaccine manufacturing processes are being optimized to increase production capacity and reduce costs.. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Market Drivers

Expanding immunization programs by government in developing countries is notably driving market growth. Pneumococcal disease, caused by the bacterium Streptococcus pneumoniae, is a significant global health concern, particularly for children under five and the elderly population. Pneumococcal pneumonia, an invasive form of the disease, can lead to severe complications such as sepsis, meningitis, and bacterial meningitis. Research activities and pipeline studies are ongoing to develop novel pneumococcal vaccines to address the pandemic. The current pneumococcal conjugate vaccine, which provides protection against 13 strains of Streptococcus pneumoniae, has been instrumental in reducing pneumonia cases and mortality rates. However, the need for booster doses and the emergence of antibiotic-resistant strains necessitate continued research. Immunocompromised patients, those with chronic conditions such as lung disease, chronic heart disease, diabetes, human immunodeficiency, and splenectomy, are at higher risk for pneumococcal infections. Ensuring accessibility and availability of the pneumococcal vaccine to these populations is crucial.

This can be achieved by expanding healthcare infrastructure in rural and remote areas, making the vaccine available at pharmacies and community clinics, and targeting pediatric populations. The pneumococcal vaccine is administered through various routes, including intramuscular and intradermal injections. Common side effects include redness, headache, tiredness, and generalized muscle pain. Despite these side effects, the importance of preventing pneumococcal infections far outweighs the risks. In conclusion, the pneumococcal vaccine plays a vital role in preventing and reducing the burden of pneumococcal diseases, including pneumonia, sepsis, meningitis, and sinusitis. Continued research and efforts to increase accessibility and availability of the vaccine, particularly in underserved populations, are essential to combat this contagious disease. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

Advancements in vaccine technologies is the key trend in the market. The market holds significance in the global health landscape due to the increasing prevalence of pneumococcal infections, including pneumonia and invasive pneumococcal diseases such as sepsis and meningitis. These contagious diseases pose a significant threat to various populations, particularly the immunocompromised, geriatric population, and those with underlying conditions like chronic heart disease, diabetes, human immunodeficiency, and splenectomy. Research activities and pipeline studies continue to focus on the development of novel pneumococcal vaccines to address the ongoing pandemic. One such advancement is the prominence of pneumococcal conjugate vaccines, which contain polysaccharides from Streptococcus pneumoniae attached to a carrier protein. These protein-based vaccines provide a stronger and more long-lasting immune response, making them an essential tool in preventing and controlling pneumococcal diseases.

The 13-valent pneumococcal conjugate vaccine (PCV13) is a widely used example of this technology. It protects against 13 strains of Streptococcus pneumoniae, contributing to a reduction in pneumonia cases and complications like bacterial meningitis. The vaccine is administered through various routes, including intramuscular injections and intradermal patches, and is available at pharmacies and community clinics for pediatric and adult populations. Common side effects of the pneumococcal vaccine include redness, headache, tiredness, and generalized muscle pain. However, these symptoms are typically mild and short-lived. In some cases, a booster dose may be required for optimal protection. Further, the market plays a crucial role in addressing the global burden of pneumococcal diseases, which can affect the lungs, bloodstream, and brain covering, leading to conditions like sinusitis, lung disease, and sepsis. Ongoing research and the development of novel vaccines, such as pneumococcal conjugate vaccines, continue to provide hope for preventing and controlling these diseases in various populations. Thus, such trends will shape the growth of the market during the forecast period.

Major Market Challenges

High cost of vaccine development and production is the major challenge that affects the growth of the market. The market faces a significant challenge due to the high cost associated with research and development, production, and distribution. Pneumococcal Pneumonia, an invasive disease caused by Streptococcus pneumoniae bacteria, poses a pandemic threat, particularly to vulnerable populations such as the immunocompromised, geriatric population, and those with underlying conditions like chronic heart disease, diabetes, human immunodeficiency, and splenectomy. Research activities and pipeline studies are crucial in developing novel pneumococcal vaccines to protect against various strains causing pneumonia, sepsis, meningitis, sinusitis, and lung disease. The process involves identifying target antigens, conducting laboratory experiments, and preclinical testing. This stage requires a skilled workforce, sophisticated equipment, and extensive research facilities. The high cost of vaccine development is due to the substantial investment required in various stages, including clinical trials, regulatory approvals, manufacturing facilities, and distribution. Pneumococcal conjugate vaccines and booster doses are essential in protecting against Streptococcus pneumoniae, which can cause redness, headache, tiredness, and generalized muscle pain in pneumonia patients.

Protein-based vaccines have gained prominence in the market due to their ability to offer broad protection against various strains. The routes of administration for pneumococcal vaccines include pharmacies, community clinics, pediatrics, and healthcare service facilities. Further, the high cost of pneumococcal vaccine development and production is a significant challenge in the market. The investment required in research, clinical trials supplies, regulatory approvals, manufacturing facilities, and distribution ultimately contributes to the high price of these vaccines. Ongoing research activities and pipeline studies are crucial in developing novel vaccines to protect against various strains of Streptococcus pneumoniae, which can cause invasive pneumococcal diseases like pneumonia, sepsis, meningitis, sinusitis, and lung disease. Hence, the above factors will impede the growth of the market during the forecast period

Market Customer Landscape

The market forecast report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Market Analyst Overview

The market is significant due to the increasing prevalence of pneumococcal diseases and the growing awareness about vaccine-preventable diseases. The market is driven by factors such as an aging population, rising healthcare expenditures, and the development of new and effective vaccines. Pneumococcal vaccines are essential in preventing pneumococcal infections, which can lead to serious health complications, particularly in children and the elderly. The market is segmented based on vaccine type, indication, and region. Vaccine types include conjugate vaccines and polysaccharide vaccines. Indications include preventive and therapeutic uses. Companies are focusing on research and development to introduce new and innovative vaccines to cater to the growing demand. The market is expected to grow steadily in the coming years due to these factors.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research and Growth Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size of the market and its contribution in focus to the parent market
• Detailed analysis of customer landscape covering diver of price sensitivity, adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies